(Q44801606)

6 December 2017

The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats (English)

1 reference

6 December 2017

5

P Jeffrey Conn

1 reference

6 December 2017

Una C Campbell

1

1 reference

6 December 2017

Kush Lalwani

2

1 reference

6 December 2017

Lisa Hernandez

3

1 reference

6 December 2017

Gene G Kinney

4

1 reference

6 December 2017

Linda J Bristow

6

1 reference

6 December 2017

1 September 2004

1 reference

6 December 2017

1 reference

6 December 2017

175

1 reference

6 December 2017

3

1 reference

6 December 2017

310-318

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-004-1827-5

6 December 2017

0 references

cites work

Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP

1 reference

12 December 2020

Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.

1 reference

12 December 2020

Meeting report; "Molecular neurobiological mechanisms in schizophrenia: seeking a synthesis," April 11-14, 1999

1 reference

12 December 2020

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

12 December 2020

[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization

1 reference

12 December 2020

Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats

1 reference

12 December 2020

SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats.

1 reference

12 December 2020

Effects of (+)-HA-966, CGS-19755, phencyclidine, and dizocilpine on repeated acquisition of response chains in pigeons: systemic manipulation of central glycine sites.

1 reference

12 December 2020

Direct and indirect modulation of the N-methyl D-aspartate receptor

1 reference

12 December 2020

An experimental analysis of the effects of d-amphetamine and cocaine on the acquisition and performance of response chains in monkeys

1 reference

12 December 2020

Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents

1 reference

12 December 2020

Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices.

1 reference

12 December 2020

Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism

1 reference

12 December 2020

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

1 reference

12 December 2020

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia

1 reference

12 December 2020

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

1 reference

12 December 2020

Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons.

1 reference

12 December 2020

The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.

1 reference

12 December 2020

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

12 December 2020

Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain

1 reference

12 December 2020

Full and partial 5-HT1A receptor agonists disrupt learning and performance in rats.

1 reference

12 December 2020

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

12 December 2020

Reduced stress-induced hyperthermia in mGluR5 knockout mice

1 reference

12 December 2020

Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions

1 reference

12 December 2020

Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.

1 reference

12 December 2020

Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5.

1 reference

12 December 2020

Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications

1 reference

12 December 2020

Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment

1 reference

12 December 2020

Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats

1 reference

12 December 2020

Comparison of the effects of typical and atypical anxiolytics on learning in monkeys and rats.

1 reference

12 December 2020

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

12 December 2020

Effects of opioids on accuracy of a fixed-ratio discrimination in monkeys and rats.

1 reference

12 December 2020

Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain

1 reference

12 December 2020

Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone

1 reference

12 December 2020

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

12 December 2020

The effect of NMDA antagonists in the radial arm maze task with an interposed delay.

1 reference

12 December 2020

Disruption of learning by excitatory amino acid receptor antagonists.

1 reference

12 December 2020

The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity

1 reference

12 December 2020

Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

12 December 2020

Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

1 reference

12 December 2020

Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats

1 reference

12 December 2020

Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats

1 reference

12 December 2020

Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems.

1 reference

12 December 2020

Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers

1 reference

12 December 2020

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

1 reference

12 December 2020

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

12 December 2020

Effects of ketamine in normal and schizophrenic volunteers

1 reference

12 December 2020

Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608).

1 reference

12 December 2020

NMDA receptor hypofunction model of schizophrenia

1 reference

12 December 2020

Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

12 December 2020

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents.

1 reference

12 December 2020

Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

12 December 2020

The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches

1 reference

12 December 2020

Differential effects of mGluR1 and mGlur5 antagonism on spatial learning in rats

1 reference

12 December 2020

Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function.

1 reference

12 December 2020

Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist

1 reference

12 December 2020

10.1007/S00213-004-1827-5

Identifiers

DOI

1 reference

6 December 2017

1 reference